Maria Carolina Stipp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Carolina Stipp has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Acco
Department of Pharmacology, Federal University of Paraná, Curitiba, Brazil
12 shared publications Claudia Rita Corso
Department of Pharmacology, Federal University of Paraná, Curitiba, PR, Brazil; Pelé Pequeno Príncipe Research Institute, Curitiba, PR, Brazil
7 shared publications- Eliana Rezende Adami
Universidade Alto Vale do Rio do Peixe (UNIARP)
5 shared publications Claudia Martins Galindo
Department of Pharmacology, Federal University of Parana, Curitiba, PR, Brazil
4 shared publications- Giseli Klassen
Department of Basic Pathology, Laboratory of Epigenetics, Federal University of Paraná, Curitiba, PR, Brazil
4 shared publications José Ederaldo Queiroz-Telles
UFPR - Departamento de Patologia Clínica Hospital das Clínicas - UFPR R. Padre Camargo, 285 Alto da Glória Curitiba - PR 80060-240
4 shared publications
Latest Publications
- Open Access
- 3 March 2025
- Published by Springer Nature in Beni-Suef University Journal of Basic and Applied Sciences
- Vol. 14 (1) , 1-13
Implications of CYP1B1 in the treatment and prognosis of breast cancer
Background: Cytochrome P450 1B1 (CYP1B1) enzyme plays an important metabolic role, especially in the metabolism of xenobiotics, endogenous substances, and procarcinogens. It may be involved in tumor initiation and progression. High levels of CYP1B1 have been identified in aggressive breast cancer cell lineages. The aim of the present study was to identify the expression and role of this enzyme in progression, prognosis, and clinical features of breast cancer patients. Methods: Microarray paraffin-embedded tumor samples from 166 women with breast cancer were analyzed by immunohistochemical for CYP1B1. Statistical analyses were performed to correlate CYP1B1 expression with various clinical parameters among breast cancer patients. Bioinformatic tools were used to determine differential CYP1B1 mRNA and protein expression from patients in databases compared with our cohort. Results: The CYP1B1 enzyme was overexpressed in 75% of breast cancer tissues. This result remained consistent regardless of the treatment regimen. Furthermore, although it was not negatively associated with overall survival, its expression was notably higher in patients who died and in patients with ER- (estrogen receptor negative) and PR- (progesterone receptor negative) tumors and p53 (protein 53) mutation carriers. These findings align with the consulted databases, which indicated a relationship between CYP1B1 expression, tumor progression, and malignancy, suggesting its potential role as a biomarker for tumor aggressiveness. Conclusions: In conclusion, CYP1B1 showed a positive correlation with breast cancer malignancy, tumor progression, and toxicity effects in breast cancer patients. These findings emphasize the importance of CYP1B1 as a potential treatment target and its significance in the clinical management of breast cancer.
- 3 March 2025
- Published by Springer Nature in Beni-Suef University Journal of Basic and Applied Sciences
- Vol. 14 (1) , 1-13
Open AccessImplications of CYP1B1 in the treatment and prognosis of breast cancer
Background: Cytochrome P450 1B1 (CYP1B1) enzyme plays an important metabolic role, especially in the metabolism of xenobiotics, endogenous substances, and procarcinogens. It may be involved in tumor initiation and progression. High levels of CYP1B1 have been identified in aggressive breast cancer cell lineages. The aim of the present study was to identify the expression and role of this enzyme in progression, prognosis, and clinical features of breast cancer patients. Methods: Microarray paraffin-embedded tumor samples from 166 women with breast cancer were analyzed by immunohistochemical for CYP1B1. Statistical analyses were performed to correlate CYP1B1 expression with various clinical parameters among breast cancer patients. Bioinformatic tools were used to determine differential CYP1B1 mRNA and protein expression from patients in databases compared with our cohort. Results: The CYP1B1 enzyme was overexpressed in 75% of breast cancer tissues. This result remained consistent regardless of the treatment regimen. Furthermore, although it was not negatively associated with overall survival, its expression was notably higher in patients who died and in patients with ER- (estrogen receptor negative) and PR- (progesterone receptor negative) tumors and p53 (protein 53) mutation carriers. These findings align with the consulted databases, which indicated a relationship between CYP1B1 expression, tumor progression, and malignancy, suggesting its potential role as a biomarker for tumor aggressiveness. Conclusions: In conclusion, CYP1B1 showed a positive correlation with breast cancer malignancy, tumor progression, and toxicity effects in breast cancer patients. These findings emphasize the importance of CYP1B1 as a potential treatment target and its significance in the clinical management of breast cancer.
- 1 February 2023
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 24 (2) , 238-252
Impacts of COVID-19 in Breast Cancer: From Molecular Mechanism to the Treatment Approach
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more than 272 million people, resulting in 5.3 million deaths worldwide from COVID-19. Breast tumors are considered the world’s most commonly diagnosed cancer. Both breast cancer and COVID-19 share common pathogenic features, represented by inflammatory mediators and the potential of SARS-CoV-2 replication in metastatic cancer cells. This may intensify viral load in patients, thereby triggering severe COVID-19 complications. Thus, cancer patients have a high risk of developing severe COVID-19 with SARS-CoV-2 infection and a higher rate of complications and death than non-cancer patients. The present review discusses common mechanisms between COVID-19 and breast cancer and the particular susceptibility to COVID-19 in breast cancer patients. We describe the effects of chemotherapeutic agents that are used against this cancer, which should be considered from the perspective of susceptibility to SARS-CoV-2 infection and risk of developing severe events. We also present potential drug interactions between chemotherapies that are used to treat breast cancer and drugs that are applied for COVID-19. The drugs that are identified as having the most interactions are doxorubicin and azithromycin. Both drugs can interact with each other and with other drugs, which likely requires additional drug monitoring and changes in drug dosage and timing of administration. Further clinical and observational studies involving breast cancer patients who acquire COVID-19 are needed to define the best therapeutic approach when considering the course of both diseases.
- 1 February 2023
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 24 (2) , 238-252
Impacts of COVID-19 in Breast Cancer: From Molecular Mechanism to the Treatment Approach
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more than 272 million people, resulting in 5.3 million deaths worldwide from COVID-19. Breast tumors are considered the world’s most commonly diagnosed cancer. Both breast cancer and COVID-19 share common pathogenic features, represented by inflammatory mediators and the potential of SARS-CoV-2 replication in metastatic cancer cells. This may intensify viral load in patients, thereby triggering severe COVID-19 complications. Thus, cancer patients have a high risk of developing severe COVID-19 with SARS-CoV-2 infection and a higher rate of complications and death than non-cancer patients. The present review discusses common mechanisms between COVID-19 and breast cancer and the particular susceptibility to COVID-19 in breast cancer patients. We describe the effects of chemotherapeutic agents that are used against this cancer, which should be considered from the perspective of susceptibility to SARS-CoV-2 infection and risk of developing severe events. We also present potential drug interactions between chemotherapies that are used to treat breast cancer and drugs that are applied for COVID-19. The drugs that are identified as having the most interactions are doxorubicin and azithromycin. Both drugs can interact with each other and with other drugs, which likely requires additional drug monitoring and changes in drug dosage and timing of administration. Further clinical and observational studies involving breast cancer patients who acquire COVID-19 are needed to define the best therapeutic approach when considering the course of both diseases.
- 28 October 2020
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 87 (3) , 295-309
Involvement of cytochrome P450 enzymes in inflammation and cancer: a review
Cytochrome P450 (CYP) enzymes are responsible for the biotransformation of drugs, xenobiotics, and endogenous substances. This enzymatic activity can be modulated by intrinsic and extrinsic factors, modifying the organism’s response to medications. Among the factors that are responsible for enzyme inhibition or induction is the release of proinflammatory cytokines, such as interleukin-1 (IL-1), IL-6, tumor necrosis factor α (TNF-α), and interferon-γ (IFN-γ), from macrophages, lymphocytes, and neutrophils. These cells are also present in the tumor microenvironment, participating in the development of cancer, a disease that is characterized by cellular mutations that favor cell survival and proliferation. Mutations also occur in CYP enzymes, resulting in enzymatic polymorphisms and modulation of their activity. Therefore, the inhibition or induction of CYP enzymes by proinflammatory cytokines in the tumor microenvironment can promote carcinogenesis and affect chemotherapy, resulting in adverse effects, toxicity, or therapeutic failure. This review discusses the relevance of CYPs in hepatocarcinoma, breast cancer, lung cancer, and chemotherapy by reviewing in vitro, in vivo, and clinical studies. We also discuss the importance of elucidating the relationships between inflammation, CYPs, and cancer to predict drug interactions and therapeutic efficacy.
- 28 October 2020
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 87 (3) , 295-309
Involvement of cytochrome P450 enzymes in inflammation and cancer: a review
Cytochrome P450 (CYP) enzymes are responsible for the biotransformation of drugs, xenobiotics, and endogenous substances. This enzymatic activity can be modulated by intrinsic and extrinsic factors, modifying the organism’s response to medications. Among the factors that are responsible for enzyme inhibition or induction is the release of proinflammatory cytokines, such as interleukin-1 (IL-1), IL-6, tumor necrosis factor α (TNF-α), and interferon-γ (IFN-γ), from macrophages, lymphocytes, and neutrophils. These cells are also present in the tumor microenvironment, participating in the development of cancer, a disease that is characterized by cellular mutations that favor cell survival and proliferation. Mutations also occur in CYP enzymes, resulting in enzymatic polymorphisms and modulation of their activity. Therefore, the inhibition or induction of CYP enzymes by proinflammatory cytokines in the tumor microenvironment can promote carcinogenesis and affect chemotherapy, resulting in adverse effects, toxicity, or therapeutic failure. This review discusses the relevance of CYPs in hepatocarcinoma, breast cancer, lung cancer, and chemotherapy by reviewing in vitro, in vivo, and clinical studies. We also discuss the importance of elucidating the relationships between inflammation, CYPs, and cancer to predict drug interactions and therapeutic efficacy.
- 1 September 2020
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 158, 1071-1081
Polysaccharides from green sweet pepper increase the antineoplastic effect of methotrexate on mammary tumor cells
- 1 September 2020
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 158, 1071-1081
Polysaccharides from green sweet pepper increase the antineoplastic effect of methotrexate on mammary tumor cells
- Open Access
- 1 June 2020
- Published by Conselho Federal de Farmacia in Infarma - Ciências Farmacêuticas
- Vol. 32 (1) , 86-100
EFEITOS DE POLISSACARÍDEOS DO JAMBO NO MODELO TUMORAL SOLIDO DE EHRLICH EM CAMUNDONGOS
O tratamento de câncer envolve fármacos que podem causar diversos efeitos colaterais. Assim, existe uma busca por tratamentos com menor toxicidade. Dentre os compostos estudados, os polissacarídeos de plantas superiores destacam‑se como antioxidantes e antitumorais. O objetivo deste trabalho foi avaliar os efeitos antitumorais in vivo de polissacarídeos do jambo (Syzygium jambos (L.) Alston) e da associação destes com um tratamento padrão (metotrexato), utilizando como ferramenta o tumor sólido de Ehrlich em camundongos. Os grupos de camundongos inoculados com células tumorais foram: I) Controle negativo (água destilada), II) PJ 100 (polissacarídeos do jambo, 100 mg/kg), III) PJ 150, IV) PJ 250, V) Controle positivo (metotrexato dose menor – MTX 1,5 mg/kg), VI) Controle positivo (MTX dose maior – 2,5 mg/kg) e VII) PJ 250 + MTX 2,5 mg/kg. Houve redução no peso tumoral pelos PJ, principalmente com PJ 250 (‑45%), semelhante à inibição causada pelo MTX 2,5 (‑43%), enquanto a associação PJ+MTX não potencializou esta inibição. No tecido tumoral, os PJ reduziram os níveis de parâmetros inflamatórios em relação ao controle negativo, porém a redução não foi dose‑dependente. Os PJ elevaram a atividade da superóxido dismutase tumoral e não causaram alterações hematológicas. Os PJ também não causaram danos relevantes ao fígado, órgão‑alvo de toxicidade de fármacos. Conclui‑se que os PJ reduziram o crescimento do tumor de Ehrlich, provavelmente por modulação do processo inflamatório no microambiente tumoral, evidenciando o potencial adjuvante dos PJ em quimioterapias. Assim, seus efeitos deverão ser ainda investigados em outros modelos tumorais e tipos celulares.
- 1 June 2020
- Published by Conselho Federal de Farmacia in Infarma - Ciências Farmacêuticas
- Vol. 32 (1) , 86-100
Open AccessEFEITOS DE POLISSACARÍDEOS DO JAMBO NO MODELO TUMORAL SOLIDO DE EHRLICH EM CAMUNDONGOS
O tratamento de câncer envolve fármacos que podem causar diversos efeitos colaterais. Assim, existe uma busca por tratamentos com menor toxicidade. Dentre os compostos estudados, os polissacarídeos de plantas superiores destacam‑se como antioxidantes e antitumorais. O objetivo deste trabalho foi avaliar os efeitos antitumorais in vivo de polissacarídeos do jambo (Syzygium jambos (L.) Alston) e da associação destes com um tratamento padrão (metotrexato), utilizando como ferramenta o tumor sólido de Ehrlich em camundongos. Os grupos de camundongos inoculados com células tumorais foram: I) Controle negativo (água destilada), II) PJ 100 (polissacarídeos do jambo, 100 mg/kg), III) PJ 150, IV) PJ 250, V) Controle positivo (metotrexato dose menor – MTX 1,5 mg/kg), VI) Controle positivo (MTX dose maior – 2,5 mg/kg) e VII) PJ 250 + MTX 2,5 mg/kg. Houve redução no peso tumoral pelos PJ, principalmente com PJ 250 (‑45%), semelhante à inibição causada pelo MTX 2,5 (‑43%), enquanto a associação PJ+MTX não potencializou esta inibição. No tecido tumoral, os PJ reduziram os níveis de parâmetros inflamatórios em relação ao controle negativo, porém a redução não foi dose‑dependente. Os PJ elevaram a atividade da superóxido dismutase tumoral e não causaram alterações hematológicas. Os PJ também não causaram danos relevantes ao fígado, órgão‑alvo de toxicidade de fármacos. Conclui‑se que os PJ reduziram o crescimento do tumor de Ehrlich, provavelmente por modulação do processo inflamatório no microambiente tumoral, evidenciando o potencial adjuvante dos PJ em quimioterapias. Assim, seus efeitos deverão ser ainda investigados em outros modelos tumorais e tipos celulares.
- Open Access
- 1 November 2019
- Published by Elsevier in Annals of Hepatology
- Vol. 18 (6) , 918-928
The GLP-1 analog liraglutide attenuates acute liver injury in mice
- 1 November 2019
- Published by Elsevier in Annals of Hepatology
- Vol. 18 (6) , 918-928
Open AccessThe GLP-1 analog liraglutide attenuates acute liver injury in mice
- 3 July 2019
- Published by Springer Nature in Molecular Biology Reports
- Vol. 46 (5) , 4827-4841
Salvia lachnostachys Benth has antitumor and chemopreventive effects against solid Ehrlich carcinoma
Salvia lachnostachys is an herbaceous plant with anti-inflammatory, analgesic and cytotoxic properties. This study investigated the antitumor effect of an ethanolic extract of Salvia lachnostachys leaves (EES) in a solid Ehrlich carcinoma model. Ehrlich cells were inoculated subcutaneously in the right pelvic member (2 × 106 cells) in female Swiss mice. The animals were treated with vehicle (10 mL kg−1, p.o.), EES (30 and 100 mg kg−1, p.o.), or methotrexate (2.5 mg kg−1, i.p.) for 21 days (early treatment) or 14 days (late treatment) after tumor inoculation, or 10 days before tumor inoculation and continued for 21 days after tumor inoculation (chemopreventive treatment). The acute toxicity test was performed according OECD guidelines Late treatment with EES had no antitumor effect. Early treatment with 100 mg kg−1 EES prevented tumor development, increased tumor necrosis factor-α (TNF-α) levels and decreased tumor superoxide dismutase (SOD) activity, interleukin-10 (IL-10) levels and Cyclin D1 expression, and tumor cell necrosis was observed. Chemopreventive treatment with EES for 10 and 31 days prevented tumor development in the same manner. EES treatment for 31 days decreased hepatic and tumor SOD activity, tumor IL-10 levels and Cyclin D1 expression, and increased tumor reduced glutathione, N-acetylglucosaminidase, reactive oxygen species, lipid peroxidation, TNF-α levels and Nrf2 expression. No toxicity was observed in the acute toxicity assay. In conclusion, EES had an antitumor effect by inhibiting Cyclin D1 expression and increasing inflammation with early and chemopreventive treatment. Modulation of the antioxidant system also contribute for the antitumor effects of EES.
- 3 July 2019
- Published by Springer Nature in Molecular Biology Reports
- Vol. 46 (5) , 4827-4841
Salvia lachnostachys Benth has antitumor and chemopreventive effects against solid Ehrlich carcinoma
Salvia lachnostachys is an herbaceous plant with anti-inflammatory, analgesic and cytotoxic properties. This study investigated the antitumor effect of an ethanolic extract of Salvia lachnostachys leaves (EES) in a solid Ehrlich carcinoma model. Ehrlich cells were inoculated subcutaneously in the right pelvic member (2 × 106 cells) in female Swiss mice. The animals were treated with vehicle (10 mL kg−1, p.o.), EES (30 and 100 mg kg−1, p.o.), or methotrexate (2.5 mg kg−1, i.p.) for 21 days (early treatment) or 14 days (late treatment) after tumor inoculation, or 10 days before tumor inoculation and continued for 21 days after tumor inoculation (chemopreventive treatment). The acute toxicity test was performed according OECD guidelines Late treatment with EES had no antitumor effect. Early treatment with 100 mg kg−1 EES prevented tumor development, increased tumor necrosis factor-α (TNF-α) levels and decreased tumor superoxide dismutase (SOD) activity, interleukin-10 (IL-10) levels and Cyclin D1 expression, and tumor cell necrosis was observed. Chemopreventive treatment with EES for 10 and 31 days prevented tumor development in the same manner. EES treatment for 31 days decreased hepatic and tumor SOD activity, tumor IL-10 levels and Cyclin D1 expression, and increased tumor reduced glutathione, N-acetylglucosaminidase, reactive oxygen species, lipid peroxidation, TNF-α levels and Nrf2 expression. No toxicity was observed in the acute toxicity assay. In conclusion, EES had an antitumor effect by inhibiting Cyclin D1 expression and increasing inflammation with early and chemopreventive treatment. Modulation of the antioxidant system also contribute for the antitumor effects of EES.
- 1 December 2018
- Published by Elsevier in Carbohydrate Polymers
- Vol. 201, 280-292
Antineoplastic effect of pectic polysaccharides from green sweet pepper (Capsicum annuum) on mammary tumor cells in vivo and in vitro
- 1 December 2018
- Published by Elsevier in Carbohydrate Polymers
- Vol. 201, 280-292
Antineoplastic effect of pectic polysaccharides from green sweet pepper (Capsicum annuum) on mammary tumor cells in vivo and in vitro
- 1 September 2017
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 110, 228-239
Ruthenium complex exerts antineoplastic effects that are mediated by oxidative stress without inducing toxicity in Walker-256 tumor-bearing rats
- 1 September 2017
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 110, 228-239
Ruthenium complex exerts antineoplastic effects that are mediated by oxidative stress without inducing toxicity in Walker-256 tumor-bearing rats